PDE3B and abdominal aortic aneurysm: Individuals with mutations in ANGPTL4 (Angiopoietin-like4) presented a lower risk to develop diabetes mellitus (type2), those with a loss of function in PCSK9 (Proprotein convertase subtilisin/kexin type 9) showed a reduced risk of abdominal aortic aneurysm, and those treated with inhibitors of PDE3B (Phosphodiesterase 3B), presented reduced levels of triglycerides in blood (Cohen et al., 2006; Willer et al., 2013; Ahmad et al., 2016; Dewey et al., 2017; Graham et al., 2017).